Solving The Patient Diversity Problem

Source: Clinical Leader

Patient diversity remains a hot topic in clinical trials. Regulators are focused on increasing diversity in patient populations while sponsor companies, CROs, and sites continue to struggle to find the right balance of gender and ethnic participation. What everyone would like to know is where we are now and where we go from here.

In October 2020, Clinical Leader Chief Editor, Ed Miseta, had the opportunity to sit down with Cassandra Smith of Janssen, Robin Weinick of DIA, and RADM Richardae Araojo of FDA to discuss the advances we have made in patient diversity, what the FDA and sponsor companies are doing, and why there is so much more we need to do.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader